Breaking News

Regeneron Awarded $450M BARDA Contract

To manufacture and supply anti-viral antibody cocktail REGN-COV2 for the potential treatment of COVID-19.

By: Contract Pharma

Contract Pharma Staff

Regeneron Pharmaceuticals, Inc. was awarded a $450 million contract to manufacture and supply REGN-COV2 as part of Operation Warp Speed, the Biomedical Advanced Research and Development Authority (BARDA), at the U.S. Department of Health and Human Services. REGN-COV2 is Regeneron’s investigational double antibody cocktail that is currently in two Phase II/III trials for the treatment of COVID-19 and in a Phase III trial for the prevention of COVID-19 infection. Regeneron began scaling ...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters